Published in Women's Health Weekly, January 23rd, 2003
Dentonin demonstrated significant bone formation activities in several models and a favorable safety profile in preclinical toxicology studies. The IND was filed in late October leading to the administration to the first human subjects in December. This first study will address safety and pharmacokinetics in healthy volunteers. A follow on study is expected to begin in 2003 where biological activity will be assessed by monitoring biochemical markers of bone metabolism. Publications regarding the biological activities of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly